Grant: Discovery Grants Program - Individual
University of Saskatchewan
$47,000.00
Exploring soft material nanoparticles for engaging mucosal immunity
FY 2024-25
Summary
Mucosal vaccination, and intranasal administration in particular, represents an emerging strategy to enhance the immune response against respiratory pathogens. The use of nanoparticle technology creates unique opportunities to precisely deliver protein subunit vaccines by this route. For example, soft materials such as biodegradable hydrophilic polymers can adhere or penetrate the mucous barrier and be taken up by submucosal antigen presenting cells such as dendritic cells. Nanoparticles also enable the co-delivery of adjuvants, which are essential to overcome immune tolerance of protein antigens by this route. However, there is much yet to understand regarding the structure--activity relationships of this delivery mechanism, which is the focus of this program of research.
The long term goal is to be able to engineer nanoparticle-adjuvant-antigen constructs that induce specific immune responses, such as cytotoxic T cell responses for viral vaccines and generation of memory T cells, for any antigen, by revealing the fundamental drivers at the nano-bio interface.
The short term goals of this DG are to:
1) develop models of the nasal epithelium to understand how dendritic cells process NP applied to the epithelium;
2) use deep machine learning such as artificial neural networks as well as molecular dynamics to uncover relationships between nanoparticle features, common adjuvants and immune responses, in order to predict effective compositions;
3) test the immunogenicity of novel hydrophilic NP-adjuvant subunit vaccines for veterinary applications.
The methods we will employ include:
1. 3D co-culture of differentiated, mucous-producing primary epithelial cells with dendritic cells using air-liquid interface (ALI) culture, to study the differences in dendritic cell responses based on nanoparticle composition. We expect this will be different compared to direct application to dendritic cell monoculture, which is common in vaccine screening, due to cellular cross talk and mucin protein interactions.
2. Text mining of the scientific literature will be performed to generate data for artificial neural network-based analysis of key nanoparticle features, compositions, adjuvants that induce specific immune responses in vivo.
3. Novel methodologies will be applied to fabricate chitosan and hyaluronic acid nanoparticles incorporating protein antigens for vaccines against porcine (PRRSV) and bovine (BVDV) disease, screening immunogenicity in mice.
Impact : Novel methodology for nanoparticle fabrication, compositions and analysis will be developed. This study of the early stages of biological processing of NP vaccines and deep machine learning will aid researchers to design more effective vaccines. The benefits to Canada are a broadened knowledge base in the field of vaccine development, which is an area in which Canada is providing global leadership. Candidate subunit vaccines for the economically important PRRSV and BVDV diseases will be tested.
Program
Discovery Grants Program - Individual
Recipient
Location
Saskatchewan, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RGPIN-2024-06823
Name nom
Wasan, Ellen
Department département
College of Pharmacy and Nutrition
Organization id
16
Institution établissement
University of Saskatchewan
Province en
Saskatchewan
Province fr
Saskatchewan
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
47000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Exploring soft material nanoparticles for engaging mucosal immunity
Keywords
veterinary vaccines; nanoparticles; polymers; mucosal vaccines; deep learning; biophysics; tissue models; self assembling systems; biomolecules; nano-bio interface
Application summary
Mucosal vaccination, and intranasal administration in particular, represents an emerging strategy to enhance the immune response against respiratory pathogens. The use of nanoparticle technology creates unique opportunities to precisely deliver protein subunit vaccines by this route. For example, soft materials such as biodegradable hydrophilic polymers can adhere or penetrate the mucous barrier and be taken up by submucosal antigen presenting cells such as dendritic cells. Nanoparticles also enable the co-delivery of adjuvants, which are essential to overcome immune tolerance of protein antigens by this route. However, there is much yet to understand regarding the structure--activity relationships of this delivery mechanism, which is the focus of this program of research.
The long term goal is to be able to engineer nanoparticle-adjuvant-antigen constructs that induce specific immune responses, such as cytotoxic T cell responses for viral vaccines and generation of memory T cells, for any antigen, by revealing the fundamental drivers at the nano-bio interface.
The short term goals of this DG are to:
1) develop models of the nasal epithelium to understand how dendritic cells process NP applied to the epithelium;
2) use deep machine learning such as artificial neural networks as well as molecular dynamics to uncover relationships between nanoparticle features, common adjuvants and immune responses, in order to predict effective compositions;
3) test the immunogenicity of novel hydrophilic NP-adjuvant subunit vaccines for veterinary applications.
The methods we will employ include:
1. 3D co-culture of differentiated, mucous-producing primary epithelial cells with dendritic cells using air-liquid interface (ALI) culture, to study the differences in dendritic cell responses based on nanoparticle composition. We expect this will be different compared to direct application to dendritic cell monoculture, which is common in vaccine screening, due to cellular cross talk and mucin protein interactions.
2. Text mining of the scientific literature will be performed to generate data for artificial neural network-based analysis of key nanoparticle features, compositions, adjuvants that induce specific immune responses in vivo.
3. Novel methodologies will be applied to fabricate chitosan and hyaluronic acid nanoparticles incorporating protein antigens for vaccines against porcine (PRRSV) and bovine (BVDV) disease, screening immunogenicity in mice.
Impact : Novel methodology for nanoparticle fabrication, compositions and analysis will be developed. This study of the early stages of biological processing of NP vaccines and deep machine learning will aid researchers to design more effective vaccines. The benefits to Canada are a broadened knowledge base in the field of vaccine development, which is an area in which Canada is providing global leadership. Candidate subunit vaccines for the economically important PRRSV and BVDV diseases will be tested.